Bulletin
Investor Alert

Revolution Medicines Inc.

NAS: RVMD

GO
/marketstate/country/us

After Hours

 --Quotes are delayed by 20 min

Dec 2, 2022, 4:15 p.m.

/zigman2/quotes/216320743/composite

$

25.53

Change

0.00 0.00%

Volume

Volume 15,917

Quotes are delayed by 20 min

/zigman2/quotes/216320743/composite

Previous close

$ 23.66

$ 25.53

Change

+1.87 +7.90%

Day low

Day high

$23.20

$25.72

Open

52 week low

52 week high

$14.08

$28.12

Open

Lorence H. Kim

Presently, Lorence H. Kim occupies the position of Venture Partner at Third Rock Ventures LLC and Chief Financial Officer of ModernaTX, Inc. Dr. Kim is also on the board of 6 other companies.

He previously was Chief Financial Officer of Moderna, Inc. and Managing Director at Goldman Sachs & Co. LLC.

He received an MBA from The Wharton School of the University of Pennsylvania, an undergraduate degree from Harvard University, a doctorate from Perelman School of Medicine and a doctorate from the University of Pennsylvania School of Veterinary Medicine.

Transactions

Date Shares Transaction Value
07/22/2022 50,000   Acquisition at $20 per share. 1,000,000
07/12/2022 10,500   Award at $0 per share. 0

Officers and Executives

Dr. Mark A. Goldsmith
Chairman, President & Chief Executive Officer
Dr. Margaret A. Horn
Chief Operating Officer & General Counsel
Mr. Jack Anders
Chief Financial Officer
Dr. Stephen M. Kelsey
President-Research & Development
Dr. Walter Reiher
Chief Information Officer
Dr. Xiao Lin Wang
Executive Vice President-Clinical Development
Mr. Daniel Simon
Chief Business Officer
Dr. Sushil Patel
Director
Ms. Luan M. Wilfong
Senior Vice President-Human Resources
Mr. Jeff Cislini
Secretary, Senior Vice President & General Counsel
Dr. Eric Schmidt
Independent Director
Dr. Flavia Borellini
Independent Director
Dr. Lorence H. Kim
Independent Director
Ms. Elizabeth McKee Anderson
Independent Director
Mr. Alexis A. Borisy
Lead Independent Director
Dr. Thilo Schroeder
Independent Director
Dr. Barbara L. Weber
Independent Director
Link to MarketWatch's Slice.